公开(公告)号：US20220184199A1

公开(公告)日：2022-06-16

申请号：US17601949

申请日：2020-04-06

Applicant: Pfizer Inc.

Inventor： Annaliesa Sybil Anderson ,  Isis Kanevsky ,  Farid Latif Khan ,  Charles Harold Jones ,  John Michael McLaughlin

IPC: A61K39/09

Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.

公开(公告)号：US20200164056A1

公开(公告)日：2020-05-28

申请号：US16704701

申请日：2019-12-05

Applicant: PFIZER INC.

Inventor： Kathrin Ute Jansen ,  Annaliesa Sybil Anderson ,  Judith Absalon ,  Jose Miguel Aste-Amezaga ,  Johannes Frederik Beeslaar ,  David Cooper ,  John Erwin Farley ,  Leah Diane Fletcher ,  Shannon Lea Harris ,  Thomas Richard Jones ,  Isis Kanevsky ,  Lakshmi Khandke ,  Paul Liberator ,  John Lance Perez ,  Lynn Marie Phelan ,  Gary Warren Zlotnick

IPC: A61K39/095 ,  A61P31/00 ,  A61K47/64 ,  A61K31/7028 ,  A61K47/26 ,  A61K47/10 ,  A61K47/18 ,  C07K16/12 ,  C07K14/22 ,  A61K39/12

Abstract: In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide. The invention further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against N. meningitidis serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.

公开(公告)号：US20190231861A1

公开(公告)日：2019-08-01

申请号：US16196150

申请日：2018-11-20

Applicant: PFIZER INC.

Inventor： Kathrin Ute Jansen ,  Annaliesa Sybil Anderson ,  Judith Absalon ,  Jose Miguel Aste-Amezaga ,  Johannes Frederik Beeslaar ,  David Cooper ,  John Erwin Farley ,  Leah Diane Fletcher ,  Shannon Lea Harris ,  Thomas Richard Jones ,  Isis Kanevsky ,  Lakshmi Khandke ,  Paul Liberator ,  John Lance Perez ,  Lynn Marie Phelan ,  Gary Warren Zlotnick

IPC: A61K39/095 ,  A61K31/7028 ,  C07K14/22 ,  A61K47/26 ,  A61K47/64 ,  A61K47/18 ,  C07K16/12 ,  A61P31/00 ,  A61K47/10

Abstract: In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide. The invention further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against N. meningitidis serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.

公开(公告)号：US20180214532A1

公开(公告)日：2018-08-02

申请号：US15883334

申请日：2018-01-30

Applicant: PFIZER INC.

Inventor： Kathrin Ute Jansen ,  Annaliesa Sybil Anderson ,  Judith Absalon ,  Jose Miguel Aste-Amezaga ,  Johannes Frederik Beeslaar ,  David Cooper ,  John Erwin Farley ,  Leah Diane Fletcher ,  Shannon Lea Harris ,  Thomas Richard Jones ,  Isis Kanevsky ,  Lakshmi Khandke ,  Paul Liberator ,  John Lance Perez ,  Lynn Marie Phelan ,  Gary Warren Zlotnick

IPC: A61K39/095 ,  C07K14/22 ,  C07K16/12 ,  A61K31/7028 ,  A61K47/10 ,  A61K47/26 ,  A61K47/18

CPC classification number: A61K39/095 ,  A61K31/7028 ,  A61K47/10 ,  A61K47/183 ,  A61K47/26 ,  A61K47/6415 ,  A61K47/646 ,  A61P31/00 ,  C07K14/22 ,  C07K16/1217

Abstract: In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide. The invention further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against N. meningitidis serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.